Search Within

Joachim Yahalom

  1. "Sean Devlin"
Formats
  1. Meeting Abstract (8)
  2. Journal Article (6)
Groups
  1. Biostatistics Service (14)
  2. Bone Marrow Transplant (14)
  3. CTCR Scholars (14)
  4. Center for Hematologic Malignancies (14)
  5. Department of Medicine (14)
  6. Epidemiology and Biostatistics (14)

More Groups

People
  1. Sean Devlin (14)
  2. Gunjan Shah (13)
  3. Michael Scordo (13)
  4. Miguel-Angel Perales (12)
  5. Parastoo Dahi (12)
  6. Maria Palomba (11)

More People

Years
  1. 2024 (4)
  2. 2023 (4)
  3. 2022 (1)
  4. 2020 (3)
  5. 2017 (1)
  6. 2016 (1)
Publications
  1. Blood (4)
  2. Blood Advances (2)
  3. International Journal of Radiation Oncology, Biology, Physics (2)
  4. Biology of Blood and Marrow Transplantation (1)
  5. Bone Marrow Transplantation (1)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. American Society of Hematology (6)
  2. Elsevier Inc. (4)
  3. Nature Publishing Group (2)
  4. American Association for Cancer Research (1)
  5. Oxford University Press (1)

Results (14)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Central nervous system bridging radiotherapy (CNS-BRT) achieves rapid cytoreduction prior to car T-cell therapy for aggressive B-cell lymphomas
    Meeting Abstract

    Cederquist, G.; Schefflein, J.; Devlin, S.; Shah, G.; Shouval, R.; Hubbeling, H.; Tringale, K.; Fregonese, B.; Hajj, C.; Boardman, A.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Improvement in radiomic features following bridging therapy is prognostic for CD19 chimeric antigen receptor (CAR) T-cell therapy outcome
    Meeting Abstract

    Hubbeling, H. G.; Leithner, D.; Silverman, E. A.; Flynn, J.; Devlin, S.; Shah, G. L.; Fregonese, B.; Bedmutha, A.; Boardman, A.; Dahi, P. B.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B-cell lymphoma
    Journal Article

    Hubbeling, H.; Leithner, D.; Silverman, E. A.; Flynn, J.; Devlin, S.; Shah, G.; Fregonese, B.; Wills, B.; Bedmutha, A.; Alarcon Tomas, A.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas
    Journal Article

    Cederquist, G. Y.; Schefflein, J.; Devlin, S. M.; Shah, G. L.; Shouval, R.; Hubbeling, H.; Tringale, K.; Tomas, A. A.; Fregonese, B.; Hajj, C.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • CNS radiotherapy as bridging prior to CAR T-cell therapy for non-Hodgkin B-cell lymphoma
    Meeting Abstract

    Cederquist, G.; Schefflein, J.; Devlin, S. M.; Hubbeling, H.; Tringale, K.; Shah, G. L.; Tomas, A. A.; Shouval, R.; Hajj, C.; Fregonese, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T-cell therapy outcome
    Meeting Abstract

    Hubbeling, H.; Leithner, D.; Silverman, E. A.; Flynn, J. R.; Devlin, S. M.; Shah, G. L.; Fregonese, B.; Bedmutha, A.; Wills, B.; Tomas, A. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Bridging radiation rapidly and effectively cytoreduces high-risk relapsed/refractory aggressive B cell lymphomas prior to chimeric antigen receptor T cell therapy
    Journal Article

    Hubbeling, H.; Silverman, E. A.; Michaud, L.; Tomas, A. A.; Shouval, R.; Flynn, J.; Devlin, S.; Wijetunga, N. A.; Tringale, K. R.; Batlevi, C.; more...
    Transplantation and Cellular Therapy (2023)

    Fulltext@MSK | Save
  • Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma
    Journal Article

    Alarcon Tomas, A.; Fein, J. A.; Fried, S.; Flynn, J. R.; Devlin, S. M.; Fingrut, W. B.; Anagnostou, T.; Alperovich, A.; Shah, N.; Fraint, E.; more...
    Leukemia (2023)

    Fulltext@MSK | Save
  • Patterns of relapse and risk reduction following tumor debulking by bridging radiotherapy prior to chimeric antigen receptor T cell therapy in non-Hodgkin lymphoma
    Meeting Abstract

    Hubbeling, H. G.; Silverman, E. A.; Michaud, L.; Flynn, J.; Devlin, S.; Wijetunga, N. A.; Alarcon Tomas, A.; Shouval, R.; Palomba, M. L.; Batlevi, C. L.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • A pilot study evaluating lenalidomide and CC-486 in combination with radiotherapy for patients with plasmacytoma (LENAZART study)
    Meeting Abstract

    Shah, U. A.; Werner, K.; Tavitian, E.; Devlin, S.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Tan, C.; Lu, S. X.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save